Drug Therapy For Torsade de Pointes


*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations


Torsade de Pointes. Torsade de pointes is an uncommon and unique type of ventricular tachycardia. It differs from other forms of ventricular tachycardia by its morphological features, underlying mechanism, and modes of therapy. Recognizing torsade de pointes is of major clinical importance, as standard antiarrhythmic regimens might not only be ineffective in abolishing this life‐threatening arrhythmia but may aggravate it. Torsade de pointes is most commonly precipitated by QT prolonging drugs, mainly type IA antiarrhythmic therapy such as quinidine and disopyramide, and other antiarrhythmic agents are reported to cause torsade de pointes as well. Predisposing factors known to increase the likelihood of developing torsade de pointes are: electrolyte imbalance (hypokalemia, hypomagnesemia, or both) and slow heart rate induced either by sinus bradycardia or heart block. Treatment of torsade de pointes is aimed at shortening the QT interval. By acceleration of the heart rate, the QT interval is shortened, thus preventing the recurrence of the arrhythmia. Treatment of torsade de pointes includes: isoproterenol infusion, cardiac pacing, and intravenous atropine. Intravenous magnesium sulfate, a relatively new mode of therapy for torsade de pointes, was proven to be extremely effective and is now regarded as the treatment of choice for this arrhythmia.(Cardiovasc Electrophysiol, Vol. 4, pp. 206–210, April 1993)

Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalJournal of Cardiovascular Electrophysiology
Issue number2
StatePublished - Apr 1993
Externally publishedYes


  • calcium
  • early afterdepolarization
  • long QT
  • magnesium
  • ventricular tachycardia


Dive into the research topics of 'Drug Therapy For Torsade de Pointes'. Together they form a unique fingerprint.

Cite this